stimOS GmbH raised a a Series A funding round from WEFA Inotec, HTGF and MBG

stimOS GmbH, a Constance, Germany-based manufacturer of medical technology, announced that it secured a Series A funding round of undisclosed amount.

Funding was provided by strategic investor WEFA Inotec GmbH, a German manufacturer of extrusion tooling, precision technology and CVD coatings, and included funding from HTGF, MBG and founding partner Dietmar Schaffarczyk, who are increasing their shares.

The proceeds will be used to turn the patented “Mimicking Bone Technology (MBT)” into an internationally industrial benchmark and to establish the technology as the golden standard for osseointegrative implant surfaces.

stimOS has developed MBT, a biochemical process that initiates the formation of healthy bone, has anti-inflammatory effects, provides acute anchoring of the implants and improves healing substantially. Instead of relying on existing coating technologies, the company restructures implant materials in a biochemical way by using a covalently bonded activation layer: MBT imparts cell-biological properties onto inert materials, as known from nature and naturally occurring in the patient’s body. The MBT process is currently being adapted for high volumes in order to ensure comprehensive patient care.